Internal Medicine, Rheumatology · Webster, TX
NPI
1316935836
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
905 W Medical Center Blvd Ste 305
Webster, TX, 77598
Phone (281) 724-8184
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.8M
230,706 services
Medicare patients, 2024
582
Average age 73
Drug cost, 2024
$4.9M
8,310 prescriptions
Company payments, 2025
$3,513
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Abdelnaser Elkhalili was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 84,800 times for 24 patients. In total Abdelnaser Elkhalili billed 230,706 services in 71 codes, and Medicare paid $3.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-19.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 84,800 | 24 | $3.46 | $293K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 50,020 | 71 | $33.93 | $1.7M |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 16,385 | 14 | $8.57 | $140K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 6,707 | 11 | $9.09 | $61K |
| J0897 Injection, denosumab, 1 mg | Office | 5,285 | 56 | $20.63 | $109K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 3,510 | 11 | $25.05 | $88K |
| 99214 Office E&M - Established | Office | 1,503 | 384 | $95.96 | $144K |
| J7322 Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 1,416 | 16 | $12.95 | $18K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,414 | 39 | $0.23 | $324 |
| J7325 Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | Office | 1,056 | 14 | $7.08 | $7,477 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,045 | 113 | $0.74 | $773 |
| 96413 Chemotherapy Administration | Office | 938 | 109 | $98.20 | $92K |
| 96401 Chemotherapy Administration | Office | 695 | 91 | $52.48 | $36K |
| 99215 Office E&M - Established | Office | 509 | 236 | $127.81 | $65K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 440 | 88 | $4.71 | $2,071 |
By year: 2022 $4.2M for 198,182 services; 2023 $3.7M for 194,781 services; 2024 $3.8M for 230,706 services.
Medicare prescription drug claims, 2024
In 2024, the drug Abdelnaser Elkhalili prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,059 prescriptions and refills. In total Abdelnaser Elkhalili wrote 8,310 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,059 | 2,762 | 339 | $41K |
| Gabapentin Generic | 776 | 1,268 | 197 | $7,788 |
| Meloxicam Generic | 514 | 1,413 | 251 | $3,984 |
| Allopurinol Generic | 512 | 1,398 | 153 | $4,410 |
| Prednisone Generic | 507 | 822 | 242 | $2,187 |
| Methotrexate Methotrexate Sodium | 503 | 1,278 | 152 | $15K |
| Leflunomide Generic | 453 | 1,167 | 155 | $34K |
| Tizanidine Hcl Generic | 218 | 233 | 97 | $937 |
| Alendronate Sodium Generic | 213 | 576 | 99 | $2,237 |
| Diclofenac Sodium Generic | 206 | 241 | 94 | $11K |
| Duloxetine Hcl Generic | 205 | 387 | 46 | $4,321 |
| Orencia Abatacept/Maltose | 172 | 172 | 21 | $813K |
| Tramadol Hcl Generic | 171 | 171 | 48 | $547 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 161 | 161 | 69 | $2,271 |
| Pregabalin Generic | 140 | 172 | 34 | $2,461 |
Brand drugs: 1,024 claims; generic drugs: 7,265 claims; opioid claims: 401.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Abdelnaser Elkhalili $3,513 ($3,513 in general payments such as food, travel and fees) from 14 companies. The largest payer was Abbvie Inc. with $606.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 30 | $606 |
| Amgen Inc. AMGN | 35 | $599 |
| UCB, Inc. UCB.BR | 18 | $451 |
| GlaxoSmithKline, LLC. GSK | 16 | $312 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $303 |
| Janssen Biotech, Inc. JNJ | 10 | $269 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $187 |
| ANI Pharmaceuticals, Inc. ANIP | 9 | $181 |
| Mallinckrodt Hospital Products Inc. | 11 | $177 |
| Alexion Pharmaceuticals, Inc. AZN | 5 | $149 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.